secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0000950170-23-058279
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon reports Phase 1b data: tegoprubart prevents rejection with eGFR >70 in kidney transplant
--------------------------------------------------------------------------------

- Data from 11 participants showed no graft loss or death; one mild T cell mediated rejection (Banff 1a) on day 99 treated successfully.
- Aggregate mean eGFR above 70 mL/min/1.73m2 after day 90; no hyperglycemia, new onset diabetes, tremor, or CMV infection seen.
- Phase 2 BESTOW trial comparing tegoprubart vs. tacrolimus underway; enrollment of ~120 participants expected to complete end of 2024.
- One participant completed 1-year study with eGFR of 91 at day 374 and enrolled in Phase 2 open-label extension.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000095017023058279/0000950170-23-058279-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000095017023058279/eldn-20231102.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-058279

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer